gp100:209-217(210M) peptide vaccine

BIOLOGICAL4 trials

Sponsors

National Cancer Institute (NCI), University of Southern California, Bristol-Myers Squibb

Conditions

Intraocular MelanomaMelanoma (Skin)Recurrent MelanomaStage IA Skin MelanomaStage IB Skin MelanomaStage IIA Skin MelanomaStage IIB Skin MelanomaStage IIC Skin Melanoma

Phase 1

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

CompletedNCT01989559

National Cancer Institute (NCI)Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma +7

Start: 2002-10-31End: 2013-09-30Updated: 2015-01-26

Phase 2

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

CompletedNCT00005949

National Cancer Institute (NCI)Recurrent Melanoma, Stage IV Melanoma

Start: 2001-03-31Updated: 2013-01-16

Vaccine Therapy in Treating Patients With Metastatic Melanoma

CompletedNCT00334776

University of Southern CaliforniaIntraocular Melanoma, Melanoma (Skin)

Start: 2003-10-31End: 2005-06-30Updated: 2014-05-21

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

WithdrawnNCT00357461

Bristol-Myers SquibbMelanoma (Skin)

Start: 2006-05-31Updated: 2013-05-15